Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older patients with acute myeloid leukemia

Acute myeloid leukemia (AML) predominantly occurs in older adults over 65 years, who exhibit a lower tolerance to conventional induction chemotherapy (IC) compared with younger patients. Despite treatment with IC, older patients with AML have poor long-term survival without hematopoietic stem cell transplantation (HSCT). For the past decade, DNA-hypomethylating agents such as decitabine have been considered a safer alternative for patients who are unfit for IC. Prolonged (10-day) decitabine treatment has shown promising efficacy in previous studies with older patients with AML, and may be a more suitable treatment before HSCT than IC in fit patients.

The open-label randomized phase III study of the EORTC Leukemia group, GIMEMA, CELG, and GMDSSG (NCT02172872) compared the efficacy and safety of 10-day decitabine with conventional 3+7 IC as a treatment before HSCT in older (≥60 years) patients with newly diagnosed AML. Patients with at least stable disease and an HLA-matched donor were encouraged to undergo HSCT after ≥1 treatment cycle.

The rate of HSCT in decitabine-treated patients was similar to IC-treated patients (40% vs 39%). Although IC achieved higher complete remission rates compared with decitabine (61% vs 48%), the overall survival was comparable, with a median overall survival of 15 months in the decitabine group and 18 months in the IC group. At 4 years, 26% of patients from the decitabine arm and 30% of patients
from the IC arm were alive. A notable difference between the treatment arms was the incidence of grade 3–5 adverse events before HSCT. Decitabine treatment showed lower incidences of febrile neutropenia, platelet reduction, oral mucositis, and diarrhea. In addition, the 30-day mortality rate was 3.6% for decitabine compared with 6.4% for IC.

In conclusion, decitabine treatment for older patients with AML exhibited a superior safety profile compared with IC while maintaining similar overall survival and rates of HSCT. The results of this study will be presented by Prof. Michael Lübbert on Saturday, June 11.

Presenter: Prof Dr med Michael Lübbert
Affiliation: Universitätsklinikum Freiburg, Freiburg, Germany
Presentation: S125 will be presented by Prof Michael Lübbert | Saturday, June 11, 2022 | 16:30 –17:45 CEST | Hall A7, Messe Wien Exhibition & Congress Center, Vienna, Austria.

About the EHA Annual Congress

Every June, EHA organizes its Annual Congress in a major European city. In 2020 and 2021, the format was virtual due to COVID-19. However, this year, EHA has organized a Hybrid congress for the first time. The Congress is aimed at health professionals working in or interested in the field of hematology. The scientific program topics range from stem cell physiology and development to leukemia, lymphoma, diagnosis and treatment, red blood cells, white blood cells and platelet disorders, hemophilia and myeloma, thrombosis and bleeding disorders, as well as transfusion and stem cell transplantation.

Back to news list

Related News

  • We are pleased to announce the release of the EORTC 2023 Annual Report

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)